Skip to main content
. 2021 Mar 3;10(2):763–774. doi: 10.1007/s40121-021-00410-0

Fig. 3.

Fig. 3

Cumulative number of cases of end-stage liver disease, liver-related deaths and HCC after increasing treatment capacity; 8-week G/P treatment would increase treatment capacity by 5064 patients compared to 12-week G/P treatment. ESLD end-stage liver disease, G/P glecaprevir/pibrentasvir, HCC hepatocellular carcinoma, LrD liver-related death, n number